AMI Pharm Advances AYP-101 to Phase 3, Redefining Fat-Reduction Injectable drug with Patient Comfort in Focus
Veröffentlicht: 11.08.2025 um 09:01 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/ami-pharm-advances-ayp-101-to-phase-3-redefining-fat-reduction-injectable-drug-with-patient-comfort-in-focus-302522991.html
en | boerse | 68029522 |
